Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2023-03.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 83 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 84 Burden of Disease of Multiple Sclerosis in Korea
Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health



Page Path
HOME > Epidemiol Health > Volume 34; 2012 > Article
Original Article
Burden of Disease of Multiple Sclerosis in Korea
Soo-Eun Chung1,2, Hae-Kwan Cheong1,2, Jae-Hyun Park1,2, Ho Jin Kim3
Epidemiol Health 2012;34:e2012008.
DOI: https://doi.org/10.4178/epih/e2012008
Published online: November 30, 2012
  • 140 Download
  • 18 Crossref

1Department of Social and Preventive Medicine, Sungkyunkwan University School of Medicine, Suwon, Korea.

2Center for Molecular Medicine, Samsung Biomedical Research Institute, Seoul, Korea.

3Department of Neurology, National Cancer Center, Goyang, Korea.

Correspondence: Hae-Kwan Cheong, MD, PhD. Department of Social and Preventive Medicine, Sungkyunkwan University School of Medicine, 2066 Seobu-ro, Jangan-gu, Suwon 440-746, Korea. Tel: +82-31-299-6300, Fax: +82-31-299-6299, hkcheong@skku.edu
• Received: May 29, 2012   • Accepted: August 31, 2012

© 2012, Korean Society of Epidemiology

This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system. There are few reports on the burden of disease of MS, worldwide. The authors aim to estimate burden of disease and estimate the epidemiologic indexes of MS in Korea using available epidemiologic data.
    Epidemiologic indexes were computed using DISMOD II software based on prevalence from nationwide survey, incidence estimated from extrapolation, mortality from National Statistics Office, and duration of disease from literature as input indexes. We calculated disability-adjusted life year (DALY) as a measure of premature mortality and disability, equivalent to years of healthy life lost due to a given condition.
    The incidence of MS in Korea was 0.1 per 100,000, higher in female than in male. The highest incidence was estimated in the age group between 35 and 44 years in male and age group between 25 and 29 years in female. Total burden of disease of MS was 1,394 DALY, comprised of 292 (21%) years of life lost and 1,101 (79%) years lived with disability. The mean age at onset of MS was 33 years old in men and 32 years old in female. Estimated duration of disease was 35 years in men and 40 years in female. Most of the DALY of MS occurred in the adult population between 25 and 54 years of age.
    Although MS is a rare disease in Korea, most of the DALY arises from young people, which results in a major financial burden on the patient, family, health system and society.
Multiple sclerosis (MS) is an chronic inflammatory disorder of central nervous system, manifesting as a widespread demyelination. It is characterized by its chronic course with intermittent relapses, finally ending up with a severe debilitation. In Korea, prevalence of MS is one of the lowest compared to the other countries in the same latitude. It is a significant public health problem, however, in that its prevalence peaks at the most productive age group, at the fourth decade [1-4]. High prevalence and subsequent life-long disability poses a heavy care burden, both direct and indirect, to household and community [3,5-7].
In Korea, MS is designated as one of the rare and intractable diseases, to which medical care cost is supported from governmental subsidy [8]. Estimation of disease burden of MS is required because it takes one of the highest priority diseases among the rare and intractable diseases. However, complex and delicate nature of the disease poses a challenge to the clinical diagnosis, which may lead to underestimation of the prevalence [7].
Prevalence of MS has wide variation depending on regions, highest prevalence is reported in the regions between 45° and 65° latitude [9]. Adjusted prevalence of MS in the United Kingdom (average latitude is 54.6 N) is 21 per 100,000, but 4 per 100,000 in northern Latin America (average latitude of 20.7 S) [2,9,10]. In Korea, Kim et al. [11] reported 3.5 per 100,000 through national survey in 2006, which is one of the lowest in the world, even compared to that of the 3.9 in 100,000 in Morioka, Japan, located at the similar latitude in the neighboring country [12,13].
There is a limitation in the use of common epidemiological indexes [6,14]. Such as incidence or prevalence in reflecting quality of life, loss due to disability, or health status after recovery [15]. For this end, indicators of more comprehensive health outcome such as disability-adjusted life years (DALY), disability-free life expectancy and quality-adjusted life year have been developed [16,17]. Among these indicators, DALY, developed by World Health Organization (WHO) enables comparison of disease burden between countries and it is widely used for its clarity and simplicity in reflecting mortality and disability in a single index [18].
WHO reported the DALY of major neurologic diseases as 11,078 person-years for Alzheimer's disease, 7,308 person-years for seizure disorders, 1,617 person-years for Parkinson disease, which takes 0.75%, 0.50%, and 0.11% of total DALY, respectively [19]. DALY for MS was 0.10%, similar to that of the Parkinson disease. Compared to neurodegenerative diseases, MS is a disease of younger population, with higher socioeconomic and public health implication. In other words, years with disability (YLD) being higher than years of life lost (YLL) in MS, it takes a higher care burden leading to economic burden of the household [7].
WHO study reported that there is more than 2.5 million MS patients worldwide, taking 6.29% of total neurologic diseases, which is expected to increase 6.39% in 2015 and 6.77% in 2030 [19]. In Canadian study, younger generation takes half of total incidence and death of MS and most of the medical expenditure was raised from treatment and care of the disease and disability, representing higher burden from disability compared to that from death [20].
In Korea, there is no estimation of disease burden of MS and WHO estimation of burden of disease may not reflect the country-specific epidemiologic indexes [8], thus having a limitation in applying to a specific country. Therefore, the authors intended to estimate the burden of disease for MS for age and gender groups, using up to date epidemiologic indexes, and to estimate other basic epidemiologic indexes for the MS.
Data source
In order to calculate the burden of disease suggested by WHO, epidemiological indexes such as prevalence, incidence, case fatality rate and remission rate are needed [18]. For prevalence, this study uses the rates by five-year age and gender groups nationwide included in the study by Kim et al. [11], which was estimated based on examined health insurance data and hospital survey on medical records.
The study is the only report of prevalence in nationwide level in Korea, and presents prevalence by age and gender for all age groups. Because there is no domestic report on incidence, data from overseas were used to estimate incidence for each five-year age group. For children and youth between 0 and 14 years of age, incidence of Japan (Fukuoka 34° of latitude), whose prevalence is most similar to that of Korea, was used [21]. For over 15 years of age for whom Japan's data were not sufficient, prevalence was estimated by using a report from Italy (Ferrara 44° of latitude). This report presents incidence and prevalence for all age groups. The study site Ferrara is located at a lower degree of latitude than other European regions but at similar latitude to Japan (26-46° of latitude). In addition, the region showed the most similar prevalence, relatively, to Asia [22].
Estimation of incidence by age was premised on the fact that prevalence and incidence are proportional to each other if the duration of disease is fixed, in order to calculate the proportion of prevalence of Italy and Korea, based on which incidence was also calculated. In this study, incidence of MS patients was missing for patients younger than 10 and older than 70, and thus gender and age were set as independent variables based on numerical values estimated from 10 to 69 years, and then a simple regression analysis was performed to calculate estimated incidence by age and gender (Figure 1). As for case fatality rate, because the data of death report of MS by National Statistics Office in Korea were assessed to be inappropriate due to underreporting, the mortality of Austria [23], which offers age- and gender-specific data, was used to be substituted with the following equation along with the calculated estimates of the MS prevalence [24]:
Case fatality=mortality/prevalence
Remission rate refers to a fraction of individuals with a disease recovering to a normal state, and '0' was applied as suggested in the Global Burden of Disease (GBD) project of WHO in consideration of the irreversible nature of MS [18]. Indexes for the calculation of burden of disease, such as disease duration and age of onset, which have not been reported domestically, were calculated by using DISMOD II software. DISMOD II is a software developed by WHO to estimate epidemiological indexes of disease based on the mathematical relationship between epidemiological indexes [25]. For input indexes, those with the most approximate values after calculation through substitution were applied to raise validity of the output.
At least three of the indexes other than age- and gender-specific population, among prevalence, incidence, mortality, disease duration and age at onset, were needed to estimate the indexes [25,26]. In this study, prevalence, incidence, case fatality and remission rates, obtained as described, were selected as input indexes and allocated them by five-year age group and gender to be used for the input indexes of the software. For disability weight, 0.68 was used, which was calculated based on the Dutch Disability Weights Group's protocol introduced in the GBD study [18,24].
Burden of disease
For comprehensive evaluation of death and disease on health effects, the following formula was used for the calculation of DALY [19,27-29]:
D isability-adjusted life year (DALY)=years of life lost (YLL)+years lived with disability (YLD)
YLL[r,K]= KCera/ (r+β)2{e- (r+β) (L+a)[- (r+β) (L+a)-1]-e- (r+β)a[- (r+β)a-1]}+[ (1-K)/r] (1-e-rL)
YLD[r,K]= D{KCera/ (r+β)2{e- (r+β) (Ld+a)[- (r+β) (Ld+as)-1]-e- (r+β)a[- (r+β)a-1]}+[ (1-K)/r] (1-e-rL)
L, average expected years remaining; r, discount rate (0.03); K, age weight modulation factor (1); a, age at death; β, age weight basis (0.04); L, average expected years remaining; D, disability weight (0.690) [17-19].
In this study, values for incidence, prevalence, case fatality, mortality, disease duration and age at onset were entered into the YLD expression, and fatality rate was added to the YLL formula for calculation. The DALY equation was applied in the same way as in the GBD study, and 0.04 (K=1) was applied as age weight β, while the discount rate was calculated to be 3%. Through this, the total DALY of MS was calculated with a unit of 100,000 population, and YLL and YLD values by gender and age, and the percentages of each value was also obtained.
The epidemiological indexes obtained by entering prevalence, estimated incidence, estimated case fatality and remission rates into DISMOD II as input variables were compared with the estimated prevalence and incidence. We found that both inputs and outputs had almost the same distribution, indicating their sufficient validity (Figure 2). The resulting prevalence of epidemiological indexes was between 2.0 and 5.8 per 100,000 in the 20 to 59 age group in men and between 2.4 and 8.4 in women per 100,000. For five-year age groups from 20 to 59, men had the highest rate (5.78/100,000/year) in the 50-54 age group, which began to decrease from over 55 years of age, whereas women had the highest rate (8.36/100,000/year) in the 45-49 age group, which began to decrease from over 50. The result of incidence output in the five-year age group between 20 and 59 by gender, men had the highest rate (0.26/100,000/year) in the 30-34 age group whereas women had the highest rate (0.42/100,000/year) in the 25-29 age group, indicating that women had a higherincidence than men (Table 1).
DALY of MS in the Korean population in 2008 was 2.9 person-years per 100,000 and women had about 44% higher rate than men. DALY of MS tended to increase from 22 to 44, peaked at 25-29, then declining from over 50 (Table 2). YLL was 117 for men and 176 for women, whereas YLD was 435 for men and 666 for women, with a total of 1,101 years. Compared to men, women had a higher in the total YLL as well as YLD (Table 2).
It is estimated that the average age at onset for MS patients in Korea is 33.2 for men and 32.2 for women, and the case fatality rate was 933.5/100,000 for men and 942.5/100,000 for women. The duration of disease or survival was 35 years for men and 40 years for women, longer in women. The disease burden of MS between 20 and 54 of age was 1,124 person-years, which is 78% of the entire DALY of 1,444 person-years (Figure 3).
DALY of MS in the entire Korean population in 2008 was estimated to be 2.9 person-years per 100,000 persons, and total DALY was higher in women than in men, and was the highest in the 20-30 age group. YLD accounted for 79% of the total, indicating that most of the burden of disease comes from the loss due to disability from the disease.
MS occurs mainly among younger people, and has high incidence among adults of productive age from 20s to 50s. Thus, DALY of age group between 20 and 54 years of age took 78% of the entire DALY. High prevalence among the younger age groups is not directly linked to death, but once diagnosed, having MS means that patients suffer from it for the rest of their lives, which add socioeconomic cost burden on corresponding population group [18,30,31].
Health indexes using standardized prevalence and incidence cannot be easily readjusted for age-weighted and health discount rate over time. Moreover, domestic research on quality of life is limited to certain diseases with high prevalence, and no research has been performed on rare diseases. There is no clear idea about the burden of disease study at the national level required for medical policies, either [15].
WHO, in GBD study, reported that the DALY for MS was 23.4 person-years per 100,000 persons [14], which accounts for 0.10% of all diseases, a much higher level compared to this study. One reason can be that the WHO study included countries with notably higher prevalence such as European countries and Canada as MS has drastically varying prevalence depending on the latitude [10]. A region at a higher degree of latitude tends to have a higher prevalence. This difference is an environmental risk factor of MS in addition to the genetic factor, and it was discovered that differences resulting from local environments and race based on the latitude of locality and migration have partial effect, but it is still unclear in terms of etiology, leaving room for controversy [4].
However, compared to the low prevalence and incidence among Asian races, the survival has no significant correlation with latitude of other regions including Europe, and the fact that it is 25-48 years old globally with no great difference [10,11,18,29,30] means that while there clearly is an environmental difference when it comes to the occurrence of the disease, pathogenesis characteristics such as disease's progress and age had little difference.
The burden of disease of MS estimated in this study cannot be compared with other rare diseases due to lack of research data on them, but when compared with individual diseases studied in Korea such as chronic illnesses, it was at a very low level [17]. In terms of demographic characteristics, DALY of 20-54 years old accounted for the majority of MS, but DALY of all neurological disorders took up 63.3%, or the majority, in the age group of over 55 in the aged population, showing a different trend from MS [11,31,32]. This confirms that while MS has low incidence compared to other neurological disorders, it can bring about a huge burden as it occurs at an early age. In the case of Japan whose epidemiological characteristics have the greatest similarity to those of Korea, its incidence is slightly higher than Korea's, but its prevalence is on the steady rise [12,33]. Given that Korea's domestic circumstances are similar, one can anticipate that MS will take up a higher portion of the entire burden of disease.
This study aimed to measure disease burden of MS reflecting Korea's situations, and to that end, representative data on prevalence from hospitals and national health insurance were chosen for use among major epidemiological indexes [11]. While the data on prevalence were appropriate for use in this study as they divided patients across Korea into separate age groups, the data to calculate prevalence were insufficient due to limitations in terms of data collection. To complement this shortcoming and give sufficient consideration to the domestic circumstances, a country in Asia whose racial and regional characteristics are the closest to those of Korea, in order to calculate estimated incidence. Of the collected literature, data of Japan as a neighboring country were chosen as the most suitable candidate that satisfied the aforementioned conditions.
However, for missing incidence rates among a few specific age groups, the study team was unable to find data among Asian countries with similar racial and geographical characteristics that could fill in the gap for the Japan's missing data. As such, the study team chose the data from Ferrara, Italy, which is located at a relatively approximate degree of latitude of European countries through literature survey that gave maximum consideration to regional characteristics [23].
The study on MS of the Ferrara region offers accurate reports of the local population and includes all incidence and prevalence by gender and age group with high data reliability. Hence, the data were considered to provide a sufficient basis to supplement the missing data. Values calculated by using such data were applied to a regression equation in consideration of the relations between domestic incidence and prevalence, as well as domestic circumstances, to estimate the final incidence in Korea.
When this was cross-examined with the outcome from DISMOD II, the overall incidence level and incidence distribution by age and gender were found similar to the input and output of DISMOD II, proving the estimated data's validity. The calculated duration of disease was 35 years for men and 40 years for women in consideration of mean age. While there is no domestic report on the duration of disease, it was 36 years for men and 43 years for women among MS patients in Norway. More recently, a Canadian study reported it to be 32.5-49.2 years [34], confirming its validity [30,35,36].
This study is limited in that the available data did not cover the same race in the same region, and as such they could not reflect domestic circumstances accurately. However in reality, domestic data either lack incidence, survival time and fatality rate classified into different age groups or came with restrictive conditions, which made it impossible to utilize. To address this shortage, approximate data were estimated by combining research outcomes home and abroad by considering various factors and environment in Korea. Moreover, the disability weight of other diseases studied domestically is somewhat different from the WHO standards, which indicated that criteria of MS patients have different domestic and foreign conditions. Thus it was considered impossible to reflect all conditions entirely. Even when the WHO standards, which are widely known as the world standards, were applied, they still have some discrepancies with the actual domestic environment.
Like this, estimation of prevalence of rare diseases was limited. However, when one or more accompanying disease is associated, it restricts estimation of all other diseases' burden. The fact that evaluation is impossible without calculation of correlations between different diseases is a common limitation found in any study on the burden of disease [31,32]. In the case of MS, the estimated prevalence rate was the highest among a population over 90 years of age, but this seems to be because the total population of the most aged group is drastically smaller. Because MS incidence is relatively higher among younger age groups, it often progresses without any relevance to old-age diseases and associated chronic diseases. Thus, the purpose is to calculate the burden of individual diseases.
All other studies aiming to calculate disease burden using DALY had limitations as they failed to reflect quality of life with or without disability, respectively, due to the use of a uniform method, and divide patients by age and gender only, thereby failing to acknowledge differences resulting from income levels and environment [14,24]. The prevalence data used in this study, while falling short of being a census or a large-scale cohort study, are rare epidemiological data that cover cases of a rare disease nationwide and are subdivided by age and gender. Thus, the data serve not only as a sufficient basis for a national index but also a starting point of research on burden of other diseases, as it is the only nationwide study on the burden of a rare disease. The incidence estimated in this study and the duration of disease seem to be at similar levels with overseas data with a different prevalence.
In addition, MS was found to have a slightly lower incidence rate at an old age compared to Parkinson's disease whose incidence increases with aging. From the perspective of social public health, longer years lived with disability require continued management and alternatives at the national level, and recurring and aggravating nature of the disease places disease burden on the community, subsequently leading to a huge loss [8]. Moreover, considering the reality that hospitals specializing in MS do not have fully unified criteria for diagnosis and conditions for insurance calculation, epidemiological indexes that reflect domestic circumstances are a must to develop accurate index, if for nothing else.
This study is the first of its kind in Korea that utilized reliable domestic data to calculate the burden of disease of MS. This attempt is highly meaningful because nationwide reports on the burden of MS are rarely found around the world. Also, it succeeded in estimating objective disease burden that can be compared with other diseases, thereby offering socioeconomic benefits. Moreover, it can serve as a basis of epidemiological data for an individual disease that can fill in the gap of research on rare and incurable diseases whose research has been lagging in Korea. The study will contribute to establishing economic effectiveness and priorities in implementing health policies. If more accurate indexes that consider sociodemographic and local characteristics can be obtained by applying medical cost to be calculated in the future and demographic-specific data, they can have great use as a basis for national health economy and medical policy-planning. This study should be complemented by further research that approaches improvement of quality of life of patients suffering from rare and incurable diseases in a realistic sense by showing the changing epidemiological characteristics at home and through accurate measurement of incidence and fatality of a disease to ensure accurate understanding of the level of disease burden.

The authors have no conflict of interest to declare for this study.

This article is available from: http://e-epih.org/.

  • 1. Dean G. How many people in the world have multiple sclerosis? Neuroepidemiology 1994;13:1-7. 8190200.ArticlePubMed
  • 2. Poser CM. The multiple sclerosis trait and the development of multiple sclerosis: genetic vulnerability and environmental effect. Clin Neurol Neurosurg 2006;108:227-233. 16406307.ArticlePubMed
  • 3. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146. 2917275.ArticlePubMed
  • 4. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-1517. 18970977.ArticlePubMed
  • 5. Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol 2012;19:e11-e25. 22247419.PubMed
  • 6. Cheung YH. Cost of illness and health: friendly fiscal policy. 2009. Seoul: Ministry of Health and Welfare; p 102-119 (Korean).
  • 7. Choi BH. Strategy for the future development of national health insurance. 2007. Seoul: Ministry of Health and Welfare; p 50-61 (Korean).
  • 8. An HS. A study on the selection criteria of rare disease support system. 2007. Seoul: Management Center for Health Promotion; p 45-76 (Korean).
  • 9. Risco J, Maldonado H, Luna L, Osada J, Ruiz P, Juarez A, et al. Latitudinal prevalence gradient of multiple sclerosis in Latin America. Mult Scler 2011;17:1055-1059. 21551216.ArticlePubMed
  • 10. Simpson S Jr, Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 2011;82:1132-1141. 21478203.ArticlePubMed
  • 11. Kim NH, Kim HJ, Cheong HK, Kim BJ, Lee KH, Kim EH, et al. Prevalence of multiple sclerosis in Korea. Neurology 2010;75:1432-1438. 20956788.ArticlePubMed
  • 12. Kikuchi H, Mifune N, Niino M, Ohbu S, Kira J, Kohriyama T, et al. Impact and characteristics of quality of life in Japanese patients with multiple sclerosis. Qual Life Res 2011;20:119-131. 20700657.ArticlePubMed
  • 13. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117-127. 12849268.ArticlePubMed
  • 14. Mathers C, Fat DM, Boerma JT. World Health Organization. The global burden of disease: 2004 update. 2008. Geneva: World Health Organization; p 54-84.
  • 15. Yoon SJ, Kim YI, Kim CY, Chang H. Measuring the burden of major cancers due to premature death in Korea. Korean J Prev Med 2000;33:231-238 (Korean).
  • 16. Lee H, Yoon SJ, Ahn HS. Measuring the burden of major cancers due to smoking in Korea. Cancer Sci 2006;97:530-534. 16734732.ArticlePubMed
  • 17. Oh IH, Yoon SJ, Kim EJ. The burden of disease in Korea. J Korean Med Assoc 2011;54:646-652 (Korean).Article
  • 18. World Health Organization. Neurological disorders: public health challenges. 2006. Geneva: World Health Organization; p 27-37.
  • 19. Murray CJL, Lopez AD. Harvard School of Public Health. World Health Organization. World Bank. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. 1996. Cambridge: Harvard University Press; p 1-98.
  • 20. Tator C, Bray G, Morin D. The CBANCH report--the burden of neurological diseases, disorders, and injuries in Canada. Can J Neurol Sci 2007;34:268-269. 17803022.ArticlePubMed
  • 21. Torisu H, Kira R, Ishizaki Y, Sanefuji M, Yamaguchi Y, Yasumoto S, et al. Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 2010;32:454-462. 19942388.ArticlePubMed
  • 22. Granieri E, Economou NT, De Gennaro R, Tola MR, Caniatti L, Govoni V, et al. Multiple sclerosis in the province of Ferrara: evidence for an increasing trend. J Neurol 2007;254:1642-1648. 18008026.ArticlePubMed
  • 23. Ekestern E, Lebhart G. Mortality from multiple sclerosis in Austria 1970-2001: dynamics, trends, and prospects. Eur J Neurol 2004;11:511-520. 15272894.ArticlePubMed
  • 24. Statistics Korea. Population of Korea. cited 2012 May 31. Available from: http://kosis.kr/common/meta_onedepth.jsp?vwcd=MT_CTITLE&listid=MT_CTITLE_A (Korean).
  • 25. Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ. A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr 2003;1:4. 12773212.ArticlePubMedPMC
  • 26. Leonardi M, Mathers C. Global burden of migraine in the year 2000: summary of methods and data sources. cited 2012 May 31. Available from: http://www.who.int/entity/healthinfo/statistics/bod_migraine.pdf.
  • 27. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-1276. 9142060.ArticlePubMed
  • 28. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13:700-722. 16834700.ArticlePubMed
  • 29. Ragonese P, Aridon P, Mazzola MA, Callari G, Palmeri B, Famoso G, et al. Multiple sclerosis survival: a population-based study in Sicily. Eur J Neurol 2010;17:391-397. 19863646.ArticlePubMed
  • 30. Ragonese P, Aridon P, Salemi G, D'Amelio M, Savettieri G. Mortality in multiple sclerosis: a review. Eur J Neurol 2008;15:123-127. 18217882.ArticlePubMed
  • 31. Lee JK, Yoon SJ, Do YK, Kwon YH, Kim CY, Park K, et al. Disability weights for diseases in Korea. Korean J Prev Med 2003;36:163-170 (Korean).
  • 32. Yoon SJ, Lee H, Shin Y, Kim YI, Kim CY, Chang H. Estimation of the burden of major cancers in Korea. J Korean Med Sci 2002;17:604-610. 12378009.ArticlePubMedPMC
  • 33. Houzen H, Niino M, Hata D, Nakano F, Kikuchi S, Fukazawa T, et al. Increasing prevalence and incidence of multiple sclerosis in northern Japan. Mult Scler 2008;14:887-892. 18573833.ArticlePubMed
  • 34. Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J, et al. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry 2012;83:61-66. 21865212.ArticlePubMed
  • 35. Lalmohamed A, Bazelier MT, Van Staa TP, Uitdehaag BM, Leufkens HG, Leufkens HG, et al. Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. Eur J Neurol 2012;19:1007-1014. 22353360.ArticlePubMed
  • 36. Zhao BX, Liu XQ, Guo YP, Yang YC, Huang HF. Multiple sclerosis. A clinical study of 70 cases. Eur Neurol 1981;20:394-400. 7285990.ArticlePubMed
Figure 1
Estimated input and output data model of incidence by age and sex in DISMOD II, males (A) and females (B).
Figure 2
Input (i) and output (o) variables in DISMOD II modeling. Calculated from prevalence, incidence, case fatality and remission in multiple sclerosis using DISMOD II, males (A) and females (B). Calculation option: piecewise linear interpolation, moving average, cubic spline. (A) males and (B) females.
Figure 3
Years of life lost (YLL), years lived with disability (YLD) and disability-adjusted life year (DALY)s due to multiple sclerosis by age in Korea. (A) Age-specific composition of YLL and YLD of MS by age group. (B) Proportion of YLL and YLD of MS by age group.
Table 1
Input and output variables in DISMOD II modeling for multiple sclerosis in Korea
Age Input
Prevalence* (100,000)
Incidence†‡ (100,000)
Case fatality†‡ (100,000)
Total population§
Male Female Male Female Male Female Male Female
0-4 0.71 0.34 0.060 0.067 0.007 0.004 938,126 870,320
5-9 0.71 0.34 0.060 0.069 0.009 0.005 1,482,622 1,354,937
10-14 0.95 1.59 0.060 0.069 0.009 0.005 1,776,997 1,588,358
15-19 0.9 3.51 0.032 0.097 0.009 0.005 1,738,188 1,538,473
20-24 2.62 4.15 0.160 0.330 91.977 62.687 1,685,748 1,550,575
25-29 2.62 4.15 0.149 0.747 128.768 104.478 2,033,618 1,911,523
30-34 4.53 6.41 0.347 0.275 413.898 297.762 2,008,237 1,889,720
35-39 4.53 6.41 0.216 0.269 643.842 574.628 2,243,495 2,141,558
40-44 5.84 5.33 0.083 0.123 919.774 705.225 2,104,253 2,007,394
45-49 5.84 5.33 0.216 0.139 1,011.751 1,097.016 2,147,505 2,100,878
50-54 4.74 4.77 0.041 0.056 1,241.695 1,436.569 1,776,842 1,744,397
55-59 4.74 4.77 0.029 0.034 1,839.547 1,671.644 1,242,203 1,255,354
60-64 2.76 3.87 0.013 0.021 1,885.536 1,880.599 974,150 1,038,552
65-69 2.76 3.87 0.018 0.039 1,756.768 1,530.599 829,526 987,096
70-74 1.32 1.86 0.007 0.007 1,793.559 1,358.210 610,634 825,685
75-79 1.32 1.86 0.000 0.026 1,747.570 1,253.733 345,459 590,729
80-84 1.32 1.86 0.000 0.026 1,655.593 783.583 163,459 345,906
85-89 1.32 1.86 0.000 0.026 735.819 888.061 65,151 167,598
90≤ 3.96 5.58 0.000 0.078 2,207.457 2,664.183 17,951 66,832
Total 3.26 3.99 NA NA NA NA 24,187,107 23,979,437

NA=not available.

*From Kim NH, et al., Prevalence of multiple sclerosis in Korea. Neurology 2010;75:1432-1438 [11].

From Torisu H, et al., Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 2010;32:454-462 [21].

From Granieri E, et al., Multiple sclerosis in the province of Ferrara: evidence for an increasing trend. J Neurol 2007;254:1642-1648 [22].

§From Statistics Korea. Population of Korea. (Internet) [24].

Table 2
Years of life lost (YLL), years lived with disability (YLD) and disability-adjusted life year (DALY)s due to multiple sclerosis in Korea
Age Male
0-4 0 23 23 0 24 24 0 46 46
5-9 0 24 24 0 25 25 0 49 49
10-14 0 24 24 0 25 25 0 49 49
15-19 0 22 22 0 48 48 0 71 71
20-24 0 21 21 0 90 90 0 110 110
25-29 31 76 107 0 164 164 31 240 271
30-34 28 86 114 0 111 111 28 197 225
35-39 25 77 102 26 81 107 50 158 208
40-44 22 40 61 23 42 65 44 82 126
45-49 18 22 41 39 36 75 58 59 116
50-54 15 9 25 33 10 44 49 19 68
55-59 13 0 13 28 8 36 41 8 49
60-64 10 0 10 11 0 11 21 0 21
65-69 8 0 8 9 0 9 17 0 17
70-74 6 0 6 7 0 7 13 0 13
75-79 0 0 0 5 0 5 5 0 5
80-84 0 0 0 0 0 0 0 0 0
85-89 0 0 0 0 0 0 0 0 0
≥90 0 0 0 0 0 0 0 0 0
Total 176 423 599 181 665 846 356 1,088 1,444

Values are presented as person years.

Figure & Data



    Citations to this article as recorded by  
    • Incidencia y prevalencia de la esclerosis múltiple en China y países asiáticos
      G.X. Zhang, A. Carrillo-Vico, W.T. Zhang, S.S. Gao, G. Izquierdo Ayuso
      Neurología.2023; 38(3): 159.     CrossRef
    • Hypophosphatemic Rickets in Colombia: A Prevalence-Estimation Model in Rare Diseases. 2018
      Jancy Andrea Huertas-Quintero, Natalia Losada-Trujillo, Diego Alberto Cuellar-Ortiz, Harvy Mauricio Velasco-Parra
      The Lancet Regional Health - Americas.2022; 7: 100131.     CrossRef
    • A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China
      Tan Guojun, Xu Yan, Wang Weizhi, Wang Lihua, Li Chunyang, Zhang Xinghu, Zhou Hongyu, Dong Huiqing, Zhang Meini, Jin Tao, Yang Huan, Cui Liying, Guo Li
      Multiple Sclerosis and Related Disorders.2022; 60: 103732.     CrossRef
    • The analysis of dynamic gene expression patterns in peripheral blood of multiple sclerosis patients indicates possible diagnostic and prognostic biomarkers
      Rabat Razia, Fazeel Majeed, Rehab Amin, Shahid Mukhtar, Khalid Mehmood, Deeba Noreen Baig
      Molecular Immunology.2022; 147: 147.     CrossRef
    • Identification of blood-derived candidate gene markers and a new 7-gene diagnostic model for multiple sclerosis
      Xin Chen, Huiqing Hou, Huimin Qiao, Haolong Fan, Tianyi Zhao, Mei Dong
      Biological Research.2021;[Epub]     CrossRef
    • Epidemiology, treatment patterns and healthcare utilizations in multiple sclerosis in Taiwan
      Chia-Yun Hsu, Long-Sun Ro, Li-Ju Chen, Chun-Wei Chang, Kuo-Hsuan Chang, I-Hsuan Wu, Amy Lin, Fei-Yuan Hsiao
      Scientific Reports.2021;[Epub]     CrossRef
    • Burden of multiple sclerosis in Iran from 1990 to 2017
      Nima Fattahi, Sahar Saeedi Moghaddam, Farnam Mohebi, Negar Rezaei, Masoud Masinaei, Sahar Mohammadi Fateh, Elham Soleymani Hassanlouei, Farhad Manoochehri, Eghbal Fattahi, Mohammad Ali Sahraian, Maziar Moradi-lakeh, Ali H. Mokdad, Mohsen Naghavi, Farshad
      BMC Neurology.2021;[Epub]     CrossRef
    • Optic neuritis in German children: clinical findings and association with multiple sclerosis
      Felix Tonagel, Helmut Wilhelm, Carina Kelbsch
      Graefe's Archive for Clinical and Experimental Ophthalmology.2020; 258(7): 1523.     CrossRef
    • Evidence of an increased prevalence of multiple sclerosis: a population-based study of Tehran registry during 1999–2018
      Amir Almasi-Hashiani, Mohammad Ali Sahraian, Sharareh Eskandarieh
      BMC Neurology.2020;[Epub]     CrossRef
    • Epstein-Barr virus infection as a predisposing factor for multiple sclerosis. An update from molecular biology, immunology and epidemiology
      David López-Valencia, Ángela Medina-Ortega, Diego Fernando Hoyos-Samboní, Jhan Sebastián Saavedra-Torres, Carolina Salguero
      Revista de la Facultad de Medicina.2019; 67(3): 305.     CrossRef
    • Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis
      Elmira Agah, Arshia Zardoui, Amene Saghazadeh, Mona Ahmadi, Abbas Tafakhori, Nima Rezaei, Heinz Wiendl
      PLOS ONE.2018; 13(1): e0190252.     CrossRef
    • Using inpatient data to estimate the prevalence of Wegener's granulomatosis in China
      Xiao Liu, Yazhou Cui, Yan Li, Chao Wang, Heng Zhao, Jinxiang Han
      Intractable & Rare Diseases Research.2016; 5(1): 31.     CrossRef
    • Estimating epidemiological data of Multiple sclerosis using hospitalized data in Shandong Province, China
      Xiao Liu, Yazhou Cui, Jinxiang Han
      Orphanet Journal of Rare Diseases.2016;[Epub]     CrossRef
    • Epidemiology of Multiple Sclerosis
      Jonathan Howard, Stephen Trevick, David S. Younger
      Neurologic Clinics.2016; 34(4): 919.     CrossRef
    • Quantifying Burden of Disease to Measure Population Health in Korea
      Jihyun Yoon, Seok-Jun Yoon
      Journal of Korean Medical Science.2016; 31(Suppl 2): S101.     CrossRef
    • Modeling the Burden of Abdominal Aortic Aneurysm in the USA in 2013
      Mark Stuntz
      Cardiology.2016; 135(2): 127.     CrossRef
    • Optic Neuritis in Korean Children: Low Risk of Subsequent Multiple Sclerosis
      Young Mi Kim, Hye Young Kim, Min Jeong Cho, Min Jung Kwak, Kyung Hee Park, Gyu Min Yeon, Yunjin Lee, Sang Ook Nam
      Pediatric Neurology.2015; 53(3): 221.     CrossRef
    • No association between CCL2 gene polymorphisms and risk of inflammatory demyelinating diseases in a Korean population
      S. Namgoong, J. S. Bae, H. S. Cheong, J.-H. Kim, J. Y. Kim, L. H. Kim, H. J. Kim, H. D. Shin
      Tissue Antigens.2014; 84(2): 223.     CrossRef

    Related articles

    Epidemiol Health : Epidemiology and Health